LuTectomy in European Urology
Ғылым және технология
The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion.
Also available as an audio podcast in all the usual places www.buzzsprout.com/904063/138...
Thanks to all the LuTectomy team and to all of our fantastic patients. And huge thanks to our funders.
Funding/Support: This investigator-initiated
study was funded by the Movember Foundation, the Australian Government
Medical Research Future Fund (MRFF) with contribution from the
EJ Whitten Foundation and Novartis.
Acknowledgements:
We thank the medical, surgical, nursing, nuclear
medicine, and administrative staff of all the departments at the Peter
MacCallum Cancer Centre who were involved in this trial. We thank the
patients who agreed to participate in the study. PSMA-617 was supplied
by Novartis and no carrier added 177Lu by the Australian Nuclear
Science and Technology Organisation (ANSTO).
We remember and thank
the late Dr John Violet for his involvement including study conception
and design.
Links:
LuTectomy paper in European Urology www.europeanurology.com/artic...
LuTectomy Editorial www.europeanurology.com/artic...
Пікірлер: 5
Well done team, this is a fantastic treatment approach and so good to see collaboration between specialist instead of silos. Which demonstrates that the following statement holds true "If you want to go fast go solo, if you want to go far go with company"; or words to that effect. In the next 3-5 years men may not even being looking at a surgery, Yah:)
Kudos to the Lutectomy trial team and may John Violet rest in peace. On one extreme, it may be worth considering Actinectomy as an alternative option. Additionally, ImmunoRLT could potentially be effective as well. Just a few hours before this podcast, Aggarwal et al. published their successful efforts in priming with a single-dose of Lu-PSMA and maintenance immunotherapy (which differs somewhat from the PRINCE trial) in the Lancet Oncology. The concept of Intra-arterial Lu-PSMA is truly fascinating, and interventional radiologists may have previously utilized angioembolization for the treatment of BPH. On the other end, there are some concerns on the long-term issues such as nephrotoxicity if RLT is applied upfront (Steinhelfer, JNM 2023). If phase 3 neoadjuvant RLT is planned, it might be beneficial to adjust for Ki-67 levels since this variable is an important predictor of BCR-FS, as indicated by the ARNEO trial.
@gu_cast
7 ай бұрын
Thanks Emran we totally agree. This is only the start of the journey for RKT in earlier prostate cancer
Love the ambiance!! Great Group.
@gu_cast
4 ай бұрын
Glad you like it! Thanks Shaheen. Declan and Renu